Hemostatic screening tests,Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT), are frequently used to assess the bleeding risk, for example before an operation or an invasive procedure. These tests can detect coagulation abnormalities (with the exception of factor XIII deficiency) but are not suitable for primary hemostasis disorders.
HORIBA Medical offers a new range of liquid, ready-to-use reagents for more accurate global screening tests:
• Yumizen G PT Liq
• Yumizen G APTT Liq 4
The Thrombin Time is a screening test to assess abnormalities of fibrinogen and to detect inhibitors against thrombin or fibrin.
• Yumizen G TT, a human thrombin for perfect assessment of fibrin formation.
D-dimers is degradation products of fibrin, biomarker for activation of plasma coagulation and/or fibrinolysis.
Yumizen G DDi 2, the universal reagent, liquid & ready to use for semi-auto and full-auto systems.
Onboard stability of two weeks.
An age-adjusted D-dimer cutoff combined with probability assessment ruled out the diagnosis of Pulmonary Embolism (PE) in emergency department patients with suspected PE. The D-dimer result should be interpreted according to the age-adjusted cutoff
Elevated DDi implies the involvement of fibrinolysis secondary to coagulation activation, which is very interesting in the diagnosis of DIC. A normal level of D-dimer has excellent negative predictive value. Measurements of D-dimer levels is useful to monitor to capture the course of the disease.
D-dimer is correlate with disease severity and a reliable prognostic biomarker for in-hospital mortality in patients admitted for COVID-19.
Thrombophilia is a disorder of haemostasis in which there is a tendency for the occurrence of thrombosis. This tendency can be inherited or acquired. HORIBA Medical offer a comprehensive range of screening assays for thrombophilia.
Antiphospholipid syndrome is defined by the presence of persistent antiphospholipid antibodies in patients with vascular thrombosis or pregnancy morbidity. HORIBA Medical offers the full range of reagents for the diagnosis of lupus anticoagulants by both the DRVVT and APTT pathways according to the international guidelines:
VKA therapy inhibits factors II, VII, IX, and X and causes a prolonged PT.
VKAs can prevent stroke or systemic embolization among patients with atrial fibrillation and can treat and prevent venous thromboembolism. The impact of VKAs on clotting is assessed via the International Normalized Ratio: INR = (PT patient/MNPT)ISI
HORIBA Medical offers a comprehensive range for monitoring of VKA therapy:
Heparin is a commonly used medication in the treatment and prophylaxis of thromboembolic disorders effective for prevention and treatment of venous thrombosis and pulmonary embolism, for prevention of mural thrombosis after myocardial infarction and for treatment of patients with unstable angina.
*This product may not be available in your country or region at this time. Please contact your HORIBA Medical sales representative or distributor for more information.
Do you have any questions or requests? Use this form to contact our specialists. * These fields are mandatory.